Joachim Gullbo

Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide-Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma

Huledal, Gunilla; Ruiz-Garcia, Ana; Kawakatsu, Sonoko; Wang, Xiaoning et al.

Part of Journal of clinical pharmacology, p. 240-252, 2024

• DOI for Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide-Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes

Byrgazov, Konstantin; Lind, Thomas; Rasmusson, Annica J.; Andersson, Claes et al.

Part of Bone Reports, 2021

• DOI for Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes

Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma

Mateos, Maria-Victoria; Blade, Joan; Bringhen, Sara; Ocio, Enrique M. et al.

Part of Journal of Clinical Medicine, 2020

• DOI for Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma
• Download full text (pdf) of Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma

Melflufen for relapsed and refractory multiple myeloma

Oriol, Albert; Larocca, Alessandra; Leleu, Xavier; Hajek, Roman et al.

Part of Expert Opinion on Investigational Drugs, p. 1069-1078, 2020

• DOI for Melflufen for relapsed and refractory multiple myeloma

Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15

Mofers, Arjan; Perego, Paola; Selvaraju, Karthik; Gatti, Laura et al.

Part of PLOS ONE, 2019

• DOI for Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15
• Download full text (pdf) of Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15

Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide-Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma

Huledal, Gunilla; Ruiz-Garcia, Ana; Kawakatsu, Sonoko; Wang, Xiaoning et al.

Part of Journal of clinical pharmacology, p. 240-252, 2024

• DOI for Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide-Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes

Byrgazov, Konstantin; Lind, Thomas; Rasmusson, Annica J.; Andersson, Claes et al.

Part of Bone Reports, 2021

• DOI for Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes

Melflufen for relapsed and refractory multiple myeloma

Oriol, Albert; Larocca, Alessandra; Leleu, Xavier; Hajek, Roman et al.

Part of Expert Opinion on Investigational Drugs, p. 1069-1078, 2020

• DOI for Melflufen for relapsed and refractory multiple myeloma

Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15

Mofers, Arjan; Perego, Paola; Selvaraju, Karthik; Gatti, Laura et al.

Part of PLOS ONE, 2019

• DOI for Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15
• Download full text (pdf) of Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15

A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors

Mody, Kabir; Mansfield, Aaron S.; Vemireddy, Lalitha; Nygren, Peter et al.

Part of Investigational new drugs, p. 684-692, 2019

• DOI for A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors

Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.

Eriksson, Anna; Chantzi, Efthymia; Fryknäs, Mårten; Gullbo, Joachim et al.

Part of Leukemia Research, p. 41-46, 2017

• DOI for Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.
• Download full text (pdf) of Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.

Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity

Karlsson, Henning; Fryknäs, Mårten; Strese, Sara; Gullbo, Joachim et al.

Part of Oncotarget, p. 30217-30234, 2017

• DOI for Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity
• Download full text (pdf) of Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity

In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia

Strese, Sara; Hassan, Saadia Bashir; Velander, Ebba; Haglund, Caroline et al.

Part of Oncotarget, p. 6341-6352, 2017

• DOI for In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia

Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma

Delforoush, Maryam; Berglund, Mattias; Edqvist, Per-Henrik; Sundström, Christer et al.

Part of European Journal of Haematology, p. 52-56, 2017

• DOI for Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma

Clinical characteristics of CNS metastases of different breast cancer subtypes - Results from a cohort study

Lindman, Henrik; Nilsson, A.; Gullbo, Joachim

Part of Cancer Research, 2017

• DOI for Clinical characteristics of CNS metastases of different breast cancer subtypes - Results from a cohort study

In vitro and in vivo activity of melflufen (J1) in lymphoma

Delforoush, Maryam; Strese, Sara; Wickström, Malin; Larsson, Rolf et al.

Part of BMC Cancer, 2016

• DOI for In vitro and in vivo activity of melflufen (J1) in lymphoma

Preclinical activity of melflufen (J1) in ovarian cancer

Carlier, Charlotte; Strese, Sara; Viktorsson, Kristina; Velander, Ebba et al.

Part of Oncotarget, p. 59322-59335, 2016

• DOI for Preclinical activity of melflufen (J1) in ovarian cancer

A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells

Ray, Arghya; Ravillah, Durgadevi; Das, Deepika S.; Song, Yan et al.

Part of British Journal of Haematology, p. 397-409, 2016

• DOI for A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells

The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells

Wang, Xin; Mazurkiewicz, Magdalena; Hillert, Ellin-Kristina; Olofsson, Maria Hagg et al.

Part of Scientific Reports, 2016

• DOI for The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells
• Download full text (pdf) of The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells

Iron chelators target both proliferating and quiescent cancer cells

Fryknäs, Mårten; Zhang, Xiaonan; Bremberg, Ulf; Senkowski, Wojciech et al.

Part of Scientific Reports, 2016

• DOI for Iron chelators target both proliferating and quiescent cancer cells
• Download full text (pdf) of Iron chelators target both proliferating and quiescent cancer cells

Repositioning Of Quinacrine For Treatment Of Acute Myeloid Leukemia - Synergies And In Vivo Effects

Eriksson, Anna; Gustafsson, Mats; Fryknäs, Mårten; Gullbo, Joachim et al.

Part of Haematologica, p. 367-368, 2016

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells

Mohell, N.; Alfredsson, J.; Fransson, A.; Uustalu, M. et al.

Part of Cell Death and Disease, 2015

• DOI for APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
• Download full text (pdf) of APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells

Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia

Eriksson, Anna; Österroos, Albin; Hassan, Sadia Bashir; Gullbo, Joachim et al.

Part of Blood Cancer Journal, 2015

• DOI for Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia
• Download full text (pdf) of Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia

Design, synthesis and biological evaluation of Novel Curcumin Analogs with anticipated anticancer activity

Fawzy, Iten M.; Youssef, Khairia M.; Ismail, Nasser S. M.; Gullbo, Joachim et al.

Part of FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES, p. 22-31, 2015

• DOI for Design, synthesis and biological evaluation of Novel Curcumin Analogs with anticipated anticancer activity

FGF2 as a potential prognostic biomarker for proneural glioma patients

Sooman, Linda; Freyhult, Eva; Jaiswal, Archita; Navani, Sanjay et al.

Part of Acta Oncologica, p. 385-394, 2015

• DOI for FGF2 as a potential prognostic biomarker for proneural glioma patients

Newly Designed and Synthesized Curcumin Analogs with in vitro Cytotoxicity and Tubulin Polymerization Activity

Fawzy, Iten M.; Youssef, Khairia M.; Ismail, Nasser S. M.; Gullbo, Joachim et al.

Part of Chemical Biology and Drug Design, p. 860-870, 2015

• DOI for Newly Designed and Synthesized Curcumin Analogs with in vitro Cytotoxicity and Tubulin Polymerization Activity

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Berglund, Åke; Ullen, Anders; Lisyanskaya, Alla; Orlov, Sergey et al.

Part of Investigational new drugs, p. 1232-1241, 2015

• DOI for First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15

Wang, Xin; D'Arcy, Padraig; Caulfield, Thomas R.; Paulus, Aneel et al.

Part of Chemical Biology and Drug Design, p. 1036-1048, 2015

• DOI for Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15

Identification of USP14 and UCHL5 As Druggable Oncotargets in Ibrutinib-Resistant Mantle Cell Lymphoma

Paulus, Aneel; Akhtar, Sharoon; Samuel, Kelara; Yousaf, Hassan et al.

Part of Blood, 2015

VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia

Paulus, Aneel; Akhtar, Sharoon; Samuel, Kelara; Yousaf, Hassan et al.

Part of Blood, 2015

The 19S Deubiquitinase Inhibitor b-AP15 Is Enriched in Cells and Elicits Rapid Commitment to Cell Death

Wang, Xin; Stafford, William; Mazurkiewicz, Magdalena; Fryknäs, Mårten et al.

Part of Molecular Pharmacology, p. 932-945, 2014

• DOI for The 19S Deubiquitinase Inhibitor b-AP15 Is Enriched in Cells and Elicits Rapid Commitment to Cell Death

Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments

Zhang, Xiaonan; Fryknäs, Mårten; Hernlund, Emma; Fayad, Walid et al.

Part of Nature Communications, p. 3295, 2014

Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments

Zhang, Xiaonan; Fryknäs, Mårten; Hernlund, Emma; Fayad, Walid et al.

Part of Nature Communications, p. 3295, 2014

• DOI for Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments
• Download full text (pdf) of Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments

PTPN6 expression is epigenetically regulated and influences survival and response to chemotherapy in high-grade gliomas

Sooman, Linda; Ekman, Simon; Tsakonas, Georgios; Jaiswal, Archita et al.

Part of Tumor Biology, p. 4479-4488, 2014

• DOI for PTPN6 expression is epigenetically regulated and influences survival and response to chemotherapy in high-grade gliomas

Repositioning of Quinacrine for Treatment of Acute Myeloid Leukemia

Eriksson, Anna; Osterros, Albin; Hassan, Sadia Bashir; Gullbo, Joachim et al.

Part of Blood, 2014

Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance

Fryknäs, Mårten; Gullbo, Joachim; Wang, Xin; Rickardson, Linda et al.

Part of BMC Cancer, p. 374, 2013

• DOI for Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance
• Download full text (pdf) of Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance

Effects of hypoxia on human cancer cell line chemosensitivity

Strese, Sara; Fryknäs, Mårten; Larsson, Rolf; Gullbo, Joachim

Part of BMC Cancer, p. 331, 2013

• DOI for Effects of hypoxia on human cancer cell line chemosensitivity
• Download full text (pdf) of Effects of hypoxia on human cancer cell line chemosensitivity

Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival

Sooman, Linda; Lennartsson, Johan; Gullbo, Joachim; Bergqvist, Michael et al.

Part of Medical Oncology, p. 638, 2013

• DOI for Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival

Microtubule inhibition causes epidermal growth factor receptor inactivation in oesophageal cancer cells

Wu, Xuping; Sooman, Linda; Lennartsson, Johan; Bergström, Stefan et al.

Part of International Journal of Oncology, p. 297-304, 2013

• DOI for Microtubule inhibition causes epidermal growth factor receptor inactivation in oesophageal cancer cells

Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines

Sooman, Linda; Ekman, Simon; Andersson, Claes; Kultima, Hanna Göransson et al.

Part of Cancer Chemotherapy and Pharmacology, p. 329-340, 2013

• DOI for Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines

Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system

Felth, Jenny; Lesiak-Mieczkowska, Karolina; Haglund, Caroline; Gullbo, Joachim et al.

Part of Investigational new drugs, p. 587-598, 2013

• DOI for Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system

The Nanoparticulate Quillaja Saponin BBE Is Selectively Active Towards Renal Cell Carcinoma

Hassan, Saadia Bashir; Gullbo, Joachim; Hu, Kefei; Berenjian, Saideh et al.

Part of Anticancer Research, p. 143-151, 2013

The traditional medical uses and cytotoxic activities of sixty-one Egyptian plants: Discovery of an active cardiac glycoside from Urginea maritima

El-Seedi, Hesham R.; Burman, Robert; Mansour, Ahmed; Turki, Zaki et al.

Part of Journal of Ethnopharmacology, p. 746-757, 2013

• DOI for The traditional medical uses and cytotoxic activities of sixty-one Egyptian plants: Discovery of an active cardiac glycoside from Urginea maritima

Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells

Jarvius, Malin; Fryknäs, Mårten; D'Arcy, Padraig; Sun, Chao et al.

Part of Biochemical and Biophysical Research Communications - BBRC, p. 117-123, 2013

• DOI for Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells

Alternative Cytotoxic Effects of the Postulated IGF-IR Inhibitor Picropodophyllin In Vitro

Wu, Xuping; Sooman, Linda; Wickström, Malin; Fryknäs, Mårten et al.

Part of Molecular Cancer Therapeutics, p. 1526-1536, 2013

• DOI for Alternative Cytotoxic Effects of the Postulated IGF-IR Inhibitor Picropodophyllin In Vitro

The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo

Strese, Sara; Wickström, Malin; Fuchs, Peder Fredlund; Fryknäs, Mårten et al.

Part of Biochemical Pharmacology, p. 888-895, 2013

• DOI for The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo

Synergistic Effects of PI3K or P38 MAPK Inhibition in Combination With Vandetanib Treatment in Glioblastoma Cells

Sooman, Linda; Ekman, Simon; Andersson, Claes; Johansson, Fredrik et al.

Part of European Journal of Cancer, 2012

• DOI for Synergistic Effects of PI3K or P38 MAPK Inhibition in Combination With Vandetanib Treatment in Glioblastoma Cells

Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity

Wu, Xuping; Hedman, Håkan; Bergqvist, Michael; Bergström, Stefan et al.

Part of Acta Oncologica, p. 69-76, 2012

• DOI for Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity

In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues

Haglund, Caroline; Åleskog, Anna; Nygren, Peter; Gullbo, Joachim et al.

Part of Cancer Chemotherapy and Pharmacology, p. 697-707, 2012

• DOI for In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues

SHP1 expression is epigenetically regulated and influences the sensitivity to chemotherapeutic agents in glioblastoma cells

Sooman, Linda; Ekman, S.; Bergqvist, Michael; Gullbo, Joachim et al.

Part of Neuro-Oncology, 2012

• DOI for SHP1 expression is epigenetically regulated and influences the sensitivity to chemotherapeutic agents in glioblastoma cells

Inhibitors and promoters of tubulin polymerization: Synthesis and biological evaluation of chalcones and related dienones as potential anticancer agents

Dyrager, Christine; Wickström, Malin; Fridén-Saxin, Maria; Friberg, Annika et al.

Part of Bioorganic & Medicinal Chemistry, p. 2659-2665, 2011

• DOI for Inhibitors and promoters of tubulin polymerization: Synthesis and biological evaluation of chalcones and related dienones as potential anticancer agents

Cytotoxic potency of small macrocyclic knot proteins: Structure-activity and mechanistic studies of native and chemically modified cyclotides

Burman, Robert; Herrmann, Anders; Tran, Rosetti; Kivelä, Jan-Erik et al.

Part of Organic and biomolecular chemistry, p. 4306-4314, 2011

• DOI for Cytotoxic potency of small macrocyclic knot proteins: Structure-activity and mechanistic studies of native and chemically modified cyclotides

Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment

Gullbo, Joachim; Fryknäs, Mårten; Rickardson, Linda; Darcy, Padraig et al.

Part of Biochemical Pharmacology, p. 139-147, 2011

• DOI for Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment

Ex Vivo Activity of Cardiac Glycosides in Acute Leukaemia

Hallböök, Helene; Felth, Jenny; Eriksson, Anna; Fryknäs, Mårten et al.

Part of PLOS ONE, 2011

• DOI for Ex Vivo Activity of Cardiac Glycosides in Acute Leukaemia

Novel activity of acriflavine against colorectal cancer tumor cells

Hassan, Saadia; Laryea, Daniel; Mahteme, Haile; Felth, Jenny et al.

Part of Cancer Science, p. 2206-2213, 2011

• DOI for Novel activity of acriflavine against colorectal cancer tumor cells

Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index

Hu, Kefei; Berenjian, Saideh; Larsson, Rolf; Gullbo, Joachim et al.

Part of International Journal of Nanomedicine, p. 51-62, 2010

The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan

Wickström, Malin; Viktorsson, Kristina; Lundholm, Lovisa; Aesoy, Reidun et al.

Part of Biochemical Pharmacology, p. 1281-1290, 2010

• DOI for The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan

Characterization of the cytotoxic properties of the benzimidazole fungicides, benomyl and carbendazim, in human tumour cell lines and primary cultures of patient tumour cells

Laryea, Daniel; Gullbo, Joachim; Isaksson, Anders; Larsson, Rolf et al.

Part of Anti-Cancer Drugs, p. 33-42, 2010

• DOI for Characterization of the cytotoxic properties of the benzimidazole fungicides, benomyl and carbendazim, in human tumour cell lines and primary cultures of patient tumour cells

Synthesis and Characterization of a Multi Ring-Fused 2-Pyridone-Based Fluorescent Scaffold

Sellstedt, Magnus; Nyberg, Anders; Rosenbaum, Erik; Engström, Patrik et al.

Part of European Journal of Organic Chemistry, p. 6171-6178, 2010

• DOI for Synthesis and Characterization of a Multi Ring-Fused 2-Pyridone-Based Fluorescent Scaffold

Evaluation of toxicity and anti-tumour activity of cycloviolacin O2 in mice.

Burman, Robert; Svedlund, Erika; Felth, Jenny; Hassan, Saadia et al.

Part of Biopolymers, p. 626-634, 2010

• DOI for Evaluation of toxicity and anti-tumour activity of cycloviolacin O2 in mice.

ChemGPS-NP mapping of chemical compounds for prediction of anticancer mode of action

Rosén, Josefin; Rickardson, Linda; Backlund, Anders; Gullbo, Joachim et al.

Part of QSAR & combinatorial science (Print), p. 436-446, 2009

• DOI for ChemGPS-NP mapping of chemical compounds for prediction of anticancer mode of action

Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug

Lövborg, Henrik; Burman, Robert; Gullbo, Joachim

Part of BMC research notes, p. 114, 2009

• DOI for Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug

Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs

Felth, Jenny; Rickardson, Linda; Rosén, Josefin; Wickström, Malin et al.

Part of Journal of natural products (Print), p. 1969-1974, 2009

• DOI for Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs

Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin

Wu, Xuping; Wanders, Alkwin; Wardega, Piotr; Tinge, B. et al.

Part of British Journal of Cancer, p. 334-343, 2009

• DOI for Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin

The alpine violet, Viola biflora, is a rich source of novel cyclotides with potent cytotoxic cytotoxicity

Herrmann, Anders; Burman, Robert; Mylne, Joshua S.; Karlsson, Gustav et al.

Part of Phytochemistry, p. 939-952, 2008

• DOI for The alpine violet, Viola biflora, is a rich source of novel cyclotides with potent cytotoxic cytotoxicity

The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro

Wickström, Malin; Haglund, Caroline; Lindman, Henrik; Nygren, Peter et al.

Part of Investigational new drugs, p. 195-204, 2008

• DOI for The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro

Establishment of a cell line from a chemotherapy resistant diffuse large B-cell lymphoma

Berglund, Mattias; Thunberg, Ulf; Fridberg, Marie; Wingren, Anette Gjörloff et al.

Part of Leukemia and Lymphoma, p. 1038-1041, 2007

• DOI for Establishment of a cell line from a chemotherapy resistant diffuse large B-cell lymphoma

Mechanism of action of cytotoxic cyclotides: cycloviolacin O2 disrupts lipid membranes

Svangård, Erika; Burman, Robert; Gunasekera, Sunithi; Lövborg, Henrik et al.

Part of Journal of natural products (Print), p. 643-647, 2007

• DOI for Mechanism of action of cytotoxic cyclotides: cycloviolacin O2 disrupts lipid membranes

The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo

Wickström, Malin; Johnsen, John Inge; Ponthan, Frida; Segerström, Lova et al.

Part of Molecular Cancer Therapeutics, p. 2409-2417, 2007

• DOI for The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo

Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients

Wickström, Malin; Danielsson, Katarina; Rickardson, Linda; Gullbo, Joachim et al.

Part of Biochemical Pharmacology, p. 25-33, 2007

• DOI for Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients

Inhibition of proteasome activity, nuclear factor-KB translocation and cell survival by the antialcoholism drug disulfiram

Lövborg, Henrik; Öberg, Fredrik; Rickardson, Linda; Gullbo, Joachim et al.

Part of International Journal of Cancer, p. 1577-1580, 2006

• DOI for Inhibition of proteasome activity, nuclear factor-KB translocation and cell survival by the antialcoholism drug disulfiram

Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model

Fryknäs, Mårten; Rickardson, Linda; Wickström, Malin; Dhar, Sumeer et al.

Part of Journal of Biomolecular Screening, p. 457-468, 2006

• DOI for Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model

Peracid dependent stereoselectivity and functional group contribution to the stereocontrol of epoxidation of (E)-alkene dipeptide isosteres

Wiktelius, Daniel; Berts, Wei; Jenmalm Jensen, Annika; Gullbo, Joachim et al.

Part of Tetrahedron, p. 3600-3609, 2006

Future Prospects for Old Chemotherapeutic Drugs in the Target-Specific Era; Pharmaceutics, Combinations, Co-Drugs and Prodrugs with Melphalan as an Example

Wickström, Malin; Lövborg, Henrik; Gullbo, Joachim

Part of Letters in Drug Design & Discovery, p. 695-703, 2006

Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles

Rickardson, Linda; Fryknäs, Mårten; Dhar, Sumeer; Lövborg, Henrik et al.

Part of British Journal of Cancer, p. 483-492, 2005

Screening for apoptosis--classical and emerging techniques.

Lövborg, Henrik; Gullbo, Joachim; Larsson, Rolf

Part of Anticancer Drugs, p. 593-9, 2005

Cytotoxic cyclotides from Viola tricolor

Svangård, Erika; Göransson, Ulf; Hocaoglu, Zozan; Gullbo, Joachim et al.

Part of Journal of natural products (Print), p. 144-7, 2004

• DOI for Cytotoxic cyclotides from Viola tricolor

Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.

Gullbo, Joachim; Lindhagen, Elin; Bashir-Hassan, Saadia; Tullberg, Marcus et al.

Part of Invest New Drugs, p. 411-20, 2004

Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguadine CHS 828

Gullbo, Joachim; Lövborg, Henrik; Dhar, Sumeer; Lukinius, Agneta et al.

Part of Anti-Cancer Drugs, p. 45-54, 2004

Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1

Gullbo, Joachim; Wickström, Malin; Tullberg, Marcus; Ehrsson, Hans et al.

Part of Journal of drug targeting (Print), p. 355-363, 2003

• DOI for Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1

Structure activity relationship for alkylating dipeptide nitrogen mustard derivatives

Gullbo, Joachim; Tullberg, Marcus; Våbeno, Jon; Ehrsson, Hans et al.

Part of Oncology Research, p. 113-132, 2003

Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-melphalanyl-p-L-fluorophenylalanine ethyl ester): Comparison with its m-L-sarcolysin analogue P2

Gullbo, Joachim; Wallinder, Charlotta; Tullberg, Marcus; Lövborg, Henrik et al.

Part of Molecular Cancer Therapeutics, p. 1331-1339, 2003

Small, novel proteins from the mistletoe Phoradendron tomentosum exhibit highly selective cytotoxicity to human breast cancer cells

Johansson, S.; Gullbo, Joachim; Lindholm, P.; Ek, B. et al.

Part of Cellular and Molecular Life Sciences (CMLS), p. 165-175, 2003

• DOI for Small, novel proteins from the mistletoe Phoradendron tomentosum exhibit highly selective cytotoxicity to human breast cancer cells

p53 status and its in vitro relationship to radiosensitivity andchemosensitivity in lung cancer.

Bergqvist, Michael; Brattstrom, Daniel; Gullbo, Joachim; Hesselius, Patrik et al.

Part of Anticancer Res, p. 1207, 2003

Antitumor activity of the alkylating oligopeptides J1(L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2(L-prolyl-m-L-fluorophenylalanine ethyl ester):comparison with melphalan.

Gullbo, Joachim; Dhar, Sumeer; Luthman, K; Ehrsson, H et al.

Part of Anticancer Drugs., p. 617, 2003

Cyclotides: a novel type of cytotoxic agents

Lindholm, Petra; Göransson, Ulf; Johansson, Senia; Claeson, Per et al.

Part of Molecular Cancer Therapeutics, p. 365-369, 2002

Ligatoxin B, a new cytotoxic protein with a novel helix-turn-helix DNA-binding domain from the mistletoe Phoradendron liga

Li, Shi-Sheng; Gullbo, Joachim; Lindholm, Petra; Larsson, Rolf et al.

Part of Biochemical Journal, p. 405-13, 2002

• DOI for Ligatoxin B, a new cytotoxic protein with a novel helix-turn-helix DNA-binding domain from the mistletoe Phoradendron liga

Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells.

Lövborg, Henrik; Martinsson, Petra; Gullbo, Joachim; Ekelund, Sara et al.

Part of Biochem Pharmacol, p. 1491, 2002

Cytotoxic activity of a new lipid formulation of doxorubicin in cell lines and primary tumor cells.

Gullbo, Joachim; Arsenau, D; Grundmark, Birgitta; Alvfors, Carina et al.

Part of Anticancer Res, p. 4191, 2002

Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells

Johansson, Senia; Lindholm, Petra; Gullbo, Joachim; Larsson, Rolf et al.

Part of Anti-Cancer Drugs, p. 475-83, 2001

Antitumor effect of suramin analogues in human tumour cell lines and primary cultures of tumour cells

Dhar, Sumeer; Gullbo, Joachim; Csoka, Katalin; Eriksson, E et al.

Part of Eur J Cancer, p. 803, 2000

Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma

Mateos, Maria-Victoria; Blade, Joan; Bringhen, Sara; Ocio, Enrique M. et al.

Part of Journal of Clinical Medicine, 2020

• DOI for Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma
• Download full text (pdf) of Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma

Melflufen: a peptidase-potentiated alkylating agent in clinical trials

Wickström, Malin; Nygren, Peter; Larsson, Rolf; Harmenberg, Johan et al.

Part of Oncotarget, p. 66641-66655, 2017

• DOI for Melflufen: a peptidase-potentiated alkylating agent in clinical trials
• Download full text (pdf) of Melflufen: a peptidase-potentiated alkylating agent in clinical trials

Eradicating Quiescent Tumor Cells by Targeting Mitochondrial Bioenergetics

Zhang, Xiaonan; De Milito, Angelo; Demiroglu-Zergeroglu, Asuman; Gullbo, Joachim et al.

Part of Trends in Cancer, p. 657-663, 2016

• DOI for Eradicating Quiescent Tumor Cells by Targeting Mitochondrial Bioenergetics

Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors

Zhang, Xiaonan; de Milito, Angelo; Olofsson, Maria Hagg; Gullbo, Joachim et al.

Part of International Journal of Molecular Sciences, p. 27313-27326, 2015

Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors

Zhang, Xiaonan; de Milito, Angelo; Olofsson, Maria Hagg; Gullbo, Joachim et al.

Part of International Journal of Molecular Sciences, p. 27313-27326, 2015

• DOI for Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors
• Download full text (pdf) of Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors

Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?

Selvaraju, Karthik; Mazurkiewicz, Magdalena; Wang, Xin; Gullbo, Joachim et al.

Part of Drug resistance updates, p. 20-29, 2015

• DOI for Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?

Aminopeptidase N (CD13) as a target for cancer chemotherapy

Wickström, Malin; Larsson, Rolf; Nygren, Peter; Gullbo, Joachim

Part of Cancer Science, p. 501-508, 2011

• DOI for Aminopeptidase N (CD13) as a target for cancer chemotherapy

Clinical value of using serological cytokeratins as therapeutic markers in thoracic malignancies

Ekman, Simon; Eriksson, Peter; Bergström, Stefan; Johansson, Peter et al.

Part of Anticancer Research, p. 3545-3553, 2007

Inhibition of the 19 S proteasome by bAP-15 in lymphoma cell lines

Delforoush, Maryam; Sun, Chao; Thomas, Strömberg; Strese, Sara et al.